Previous 10 | Next 10 |
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new ...
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Nov. 23, 2020 TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (N...
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy...
Independent Safety Monitoring Committee has completed safety review for RedHill Biopharma's (RDHL) opaganib (Yeliva, ABC294640) global Phase 2/3 study, in patients hospitalized with severe COVID-19 pneumonia, and unanimously recommended that the study continue.The recommendation is ...
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept Therapeutics...
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-...
The FDA has signed-off RedHill Biopharma's (RDHL) Phase 2/3 study evaluating RHB-107 (upamostat) in patients with symptomatic COVID-19 who do not require hospitalization.RHB-107 is an orally administered potent inhibitor of several serine proteases. RedHill licensed RHB-107 (formerly Mesupron...
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine prot...
RedHill Biopharma ([[RDHL]] -2.6%) has completed enrollment in U.S. Phase 2 study evaluating opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia. Topline data is expected in the coming weeks.The 40-subject Phase 2 trial is not pow...
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneum...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...